CARMELITA P ESCALANTE to Fibrinolytic Agents
This is a "connection" page, showing publications CARMELITA P ESCALANTE has written about Fibrinolytic Agents.
Connection Strength
0.136
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012 May; 10(5):807-14.
Score: 0.087
-
Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer. 2004 Jul; 12(7):531-6.
Score: 0.049